At-Home Ketamine Therapy in 2026: What Policy Experts and New Research Say About Telehealth Access

Why Policy Experts Are Backing At-Home Ketamine Therapy

A new policy analysis from the R Street Institute — a respected nonpartisan think tank — lays out why at-home ketamine therapy via telehealth is not only safe but essential for addressing America's mental health crisis. Their April 2026 report examines the regulatory landscape and makes a compelling case for keeping telehealth ketamine access open.

Here's what you need to know — and why this matters if you're considering at-home ketamine therapy with Kalm.

The Mental Health Crisis Demands Better Options

The numbers are staggering. Depression accounts for the largest share of disability-adjusted life years lost globally. Nearly 50% of people diagnosed with depression are classified as treatment-resistant — meaning at least two antidepressant medications have failed them.

For these individuals, standard treatments aren't working. Ketamine offers a fundamentally different approach: instead of waiting 4-6 weeks for an SSRI to maybe work, ketamine can reduce depressive symptoms and suicidality within hours, according to research cited in the R Street report.

What the R Street Institute Found

The R Street analysis highlights several critical points:

• Over 1,500 clinics now offer ketamine infusions across the US — but in-clinic treatment remains expensive ($400-800 per session) and geographically limited
• Telehealth prescribing flexibilities — extended through December 31, 2026 — have dramatically expanded access to affordable at-home ketamine therapy
• Racemic ketamine (the form used in at-home treatment) is off-patent and can be compounded affordably, unlike the brand-name nasal spray Spravato which requires in-office administration
• The FDA recognizes that medical providers can prescribe ketamine off-label for mental health conditions when other treatments have failed

In other words: the policy infrastructure supporting at-home ketamine therapy is stronger than ever in 2026.

Harvard/MGH Research Adds More Evidence

On top of the policy support, new clinical research keeps validating ketamine's effectiveness. A Harvard/Massachusetts General Hospital clinical trial announced this week is testing whether adding psychological coaching to ketamine treatment improves outcomes — building on research showing that combining therapy with ketamine gets better results.

Meanwhile, the NOX-1 breakthrough published in Molecular Psychiatry identified a molecular target that could significantly extend ketamine's antidepressant effects — potentially meaning fewer doses needed for lasting relief.

Who Benefits from At-Home Ketamine Therapy?

At-home ketamine therapy through telehealth is particularly valuable for people dealing with:

• Treatment-resistant depression — when SSRIs and other antidepressants haven't worked
• Anxiety disorders — including generalized anxiety and social anxiety
• PTSD — with new research showing ketamine's potential for trauma processing
• Chronic stress and burnout — especially when traditional talk therapy hits a wall
• Insomnia tied to depression — ketamine has shown sleep-improvement benefits

Kalm's at-home model means you don't need to find one of those 1,500 clinics, take time off work, or pay $400+ per session. Treatment starts at just $124/month with medical supervision, delivered to your door.

Is At-Home Ketamine Therapy Safe?

Safety is the most common concern — and the data is reassuring. The R Street report notes that ketamine is a Schedule III substance (low to moderate dependence risk) and has been used safely in medicine for over 50 years.

Kalm's program includes:

• Licensed medical provider oversight in all 50 states
• Structured treatment protocols with proper dosing
• Guided sessions with integration support
• Ongoing monitoring and check-ins

The comprehensive safety data supports supervised at-home ketamine as a legitimate treatment option — which is exactly why policy experts are advocating to keep telehealth access open.

What Happens After 2026?

The DEA telehealth prescribing flexibilities are currently set to expire December 31, 2026 — but the R Street report and other policy voices are pushing for permanent telehealth prescribing rules. Given the overwhelming evidence of benefit and the ongoing mental health crisis, making these flexibilities permanent is increasingly likely.

That said, now is the time to start treatment while access is at its most straightforward.

Start Your Recovery Today

91% of Kalm patients report relief within 5 days. With licensed providers in all 50 states, a price-match guarantee (we'll beat any competitor by 20%), and treatment starting at just $124/month, there's never been a better time to explore ketamine therapy.

👉 Get started with Kalm today Ready to take the next step? Get started with Kalm today. Explore the Kalm program.